Full-Time

Director – Global Regulatory Labeling Strategy

Labeling Strategy

Posted on 7/7/2025

Takeda

Takeda

10,001+ employees

Global biopharmaceutical firm; R&D-driven NMEs

Compensation Overview

$174.5k - $274.2k/yr

+ Short-term Incentives + Long-term Incentives

Massachusetts, USA

Remote

Category
Legal & Compliance (2)
,
Required Skills
Risk Management
Requirements
  • BSc degree, preferred; BA accepted. Advanced scientific degree (MSc, PhD, or PharmD) preferred.
  • 10+ years of pharmaceutical industry experience. This is inclusive of 8 years of labeling experience or combination of 6+ years regulatory and/or related experience.
  • Ability to develop & execute clear and practical regulatory strategies based on regulatory requirements, competitive landscape, key priorities and risk management and in alignment with broader business objectives.
  • Demonstrates a strong understanding of the core business aspect.
  • Ability to effectively collaborate with global cross-functional teams and to deliver engaging and valuable presentations to diverse stakeholders.
  • Ability to build a collaborative network of relationships across global cross-functional teams.
  • Demonstrate strong communication skills to transfer knowledge, convey complex regulatory information in a clear and concise manner in written, verbal and group presentation format.
  • Ability to advocate for regulatory decisions across global cross-functional teams.
  • Ability to actively listen to stakeholders, understanding their perspectives, addressing their concerns and formulating appropriate questions to verify their complete understanding.
  • Demonstrates deep understanding of analytical methodologies and problem-solving technique to handle complex problems.
  • Ability to comprehend, explain, and efficiently communicate complex labeling related regulatory issues.
  • Ability to assess complex labeling related regulatory requirements, proactively anticipate issues or opportunities and take actions before they arise, escalate to leadership, as needed, and making informed decisions aligned with portfolio priorities.
  • Ability to proactively identify risks, develop creative solutions and risk mitigation strategies, and appropriately escalate to leadership.
  • In-depth expertise of US and EU product labeling requirements, regulations, and guidelines.
  • Advanced knowledge of US and/or EU regulatory requirements and guidelines and proactive evaluation of evolving regulatory labeling landscape.
  • Understanding of other relevant regional regulatory nuances and requirements.
  • Understanding of scientific principles and regulatory/quality systems relevant to drug development.
  • Ability to independently create, revise and/or update product labeling (i.e. CCDS, USPI and EU SmPC) for regulatory submissions.
  • Ability to review product labeling for regulatory submissions and to provide pertinent feedback to ensure compliance with regulations and alignment with portfolio strategy and business objectives.
  • Ability to independently develop target labeling profile (TLP).
  • Strong understanding of global labeling processes, implications across the organization and globally, and impact of the scientific principles of quality, nonclinical and clinical data on product labeling.
  • Knowledge of Health Authority audit process and ability to participate in partner / health authority audits and inspections.
  • In depth knowledge of labeling role in project teams, and importance of cross-functional collaboration.
  • Knowledge of organizational structure, including its functions and interdependencies.
  • Demonstrates proactive project management skills and ability to independently deliver accurate and complete work while driving to designated timelines for the execution of submission plans, regulatory requirements and business objectives.
  • Demonstrates a strong strategic mindset and ability to independently align global labeling strategies with broader business objectives.
  • Ability to plan and prioritize global labeling activities and tasks for the assigned product(s) and to assign tasks appropriately.
  • Acts proactively and effectively as member of multi-disciplinary teams.
  • Ability to independently and effectively lead multi-disciplinary, cross-functional teams.
  • Displays leadership skills that foster a climate that encourages open dialogue, feedback and diverse opinion and an environment where ideas are exchanged, alignment is created and teams experiment and learn from success and failures.
  • Accurately identifies strengths and development needs in others and invests time to help enhance the skills, quality, depth and talent of their team.
  • Ability to distil complex issues and ideas down to simple comprehensible terms.
  • Embraces and demonstrates a diversity and inclusion mindset and role models these behaviors for the organization.
Responsibilities
  • Leads Labeling cross-functional teams providing leadership to foster cross-functional collaboration and driving alignment of the labeling strategy and labeling content.
  • In alignment with TAU/MPD Labeling Lead, coordinates the process to obtain labeling approval by Labeling Senior Management Cross-functional team (Global Labeling Oversight Committee - GLOC) providing leadership to foster cross-functional collaboration and drive alignment of the labeling strategy and labeling content at all levels.
  • Ensures preparation and alignment of GLOC Chair(s) and GLOC members through respective functions.
  • Independently authors new/revised TLP, CCDS, USPI and/or EU SmPC for assigned products, obtaining input and approval from all relevant functional areas with appropriate annotations and supporting documentation.
  • In a highly efficient manner, develops and executes a labeling implementation plan to incorporate new scientific, safety and clinical data, as well as Health Authority responses / feedback into CCDS, USPI and EU SmPC enabling the most up-to-date information and in compliance with labeling requirements to be provided to patients and Health Care Providers while minimizing the risk of write-offs.
  • Responsible for working with direct reports to develop and/or review the labeling implementation plan ensuring that the most up-to-date information and in compliance with labeling requirements is provided to patients and Health Care Providers while the risk of write-offs is minimized.
  • Independently authors/manages of outgoing communications regarding significant labeling changes and CCDS changes for assigned products.
  • Employs strong project management skills to coordinate global labeling sub-functions to ensure timely end to end label creation and timely Health Authority submission and key role in label negotiations with Health Authorities (leading or in conjunction with GRL).
  • Assess and interpret laws, regulations, and guidance documents relevant to the development and implementation of labeling documentation and assures that Takeda labeling content and processes conform to regulatory requirements.
  • Manages process for alignment of local labeling with CCDS for assigned products, including assessment of exceptions and deferrals.
  • Provides support to Local Affiliates for responses to health authorities requests, review of local labeling exceptions and alignment deferrals, etc.
  • Appropriately escalates issues to Global Labeling management and the Global Regulatory Lead (GRL) and proposes risk mitigation strategies for assigned products following global labeling communication guidance and proposes risk mitigation.
  • Spearhead the establishment and cultivation of powerful relationships among functions represented at the Labeling cross functional teams, including clinical, safety, medical affairs, and commercial, to ensure unparalleled communication effectiveness for labeling strategy and content.
  • Conducts precedent searches, analyzes relevant competitor labeling, health authority labeling requests for Takeda products, labeling guidance and trends; and develops strategies and labeling language for inclusion assigned product labels (TLP, CCDS, USPI, EU SmPC, others as appropriate) to ensure consistency with the overall product strategy, product claims and information in the CCDS and to ensure that Takeda products have the most competitive labeling possible; while maintaining awareness of recent in-class approvals.
  • Analyzes relevant competitor labeling and recent product approvals, health authority labeling requests for Takeda products and labeling guidance and trends at portfolio level to drive the development of essential, innovative, industry-leading product labeling to patients and health care professionals.
  • Represents Global Labeling at Global Regulatory Team (GRT).
  • Liaises with US Labeling Operations, EU Labeling Operations, Labeling Devices Lead and Labeling Compliance to ensure labeling objectives and timelines are met.
  • Embraces pivotal role in departmental and cross-functional task-forces and initiatives.
  • Supports Health Authority Inspections (US, EU, and Global) by providing labeling information requests related to assigned products and overall labeling processes.
  • Effectively manages resources and staff to ensure optimal performance and provides comprehensive guidance, supervision, and support to GLLs in carrying out their labeling responsibilities.
  • Supports the professional development of staff members and effectively manages their performance.
  • Demonstrate ownership to consistently drive the delivery of team goals fostering accountability while remaining focused on the big picture labeling strategy.
  • Oversight and accountability for labeling activities managed by external vendor(s) for assigned products, ensuring seamless coordination, timely delivery, and adherence to quality standards.
  • Actively contributes to the continuous improvement of labeling processes, identifying opportunities for optimization and implementing effective strategies to enhance agility, efficiency and accuracy.
Desired Qualifications
  • Advanced scientific degree (MSc, PhD, or PharmD) preferred.

Takeda is a global biopharmaceutical company focused on discovering and delivering medicines and vaccines to improve patient health. It relies on extensive research and development to create new molecular entities (NMEs) and bring them to market, aiming for up to 15 product launches through FY2024 from a pipeline of 11 NMEs. Revenue comes mainly from selling pharmaceutical products, supported by about 41,000 third-party suppliers worldwide. The company differentiates itself through a deep history (over 240 years), a broad portfolio of global brands, and a patient-centric approach that places patients’ needs at the center of its operations while pursuing environmental sustainability. Takeda’s goal is to advance health globally by turning scientific innovations into accessible therapies, maintaining long-term growth through steady product innovation and responsible operations.

Company Size

10,001+

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1781

Simplify Jobs

Simplify's Take

What believers are saying

  • Zasocitinib NDA submission planned FY2026 challenges Bristol Myers Squibb's Sotyktu.
  • Rusfertide PDUFA target Q3 2026 under FDA Priority Review boosts polycythemia vera pipeline.
  • Stock undervalued at ¥5,173 versus ¥6,036 fair value with post-FY2025 revenue recovery.

What critics are saying

  • VYVANSE generic erosion crushes revenue beyond FY2025 stabilization.
  • 634 US layoffs from July 2026 trigger talent exodus to Vertex.
  • JPY 150B FY2026 restructuring costs overrun delays oveporexton launch.

What makes Takeda unique

  • Takeda advances zasocitinib oral TYK2 inhibitor with positive Phase 3 LATITUDE data.
  • Takeda secures exclusive global rights to rusfertide after Protagonist opt-out.
  • Takeda restructures for $1.25B savings by FY2028 to fund multiple launches.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Wellness Program

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
BioSpace
Apr 6th, 2026
Takeda breaks up with Denali, dumps dementia drug.

Takeda breaks up with Denali, dumps dementia drug. April 6, 2026 | Takeda and Denali Therapeutics first partnered in early 2018 to advance drugs for neurodegenerative diseases. One asset, for Alzheimer's disease, was previously discontinued after an FDA hold and disappointing early data. More than eight years after linking up, Takeda and Denali Therapeutics are going their separate ways, with the Japanese pharma handing all rights to a dementia program back to Denali. Takeda's decision to terminate its partnership with Denali "was driven by strategic considerations," the California biotech said in an SEC document dated April 3, and "is not related to efficacy or safety data." The Japanese pharma informed Denali of its decision that same day, according to the securities filing. The companies inked their partnership in January 2018, with Takeda fronting $150 million and promising unspecified milestone payments. Takeda and Denali had also previously been working on the TREM2 agonist DNL919 for Alzheimer's disease - but this molecule's development path has been bumpy. In January 2022, the FDA slapped a clinical hold on the asset, though the partners at the time did not disclose why. The hold was eventually lifted, but Takeda and Denali in August 2023 nevertheless discontinued DNL919's development, pointing to Phase 1 findings suggesting the drug had only a "narrow therapeutic window." In 2021, Takeda also exercised its option to co-develop and co-commercialize DNL593, a protein replacement therapy that can cross the blood-brain barrier, for frontotemporal dementia. That asset has since been returned to Denali, the biotech said on April 3. "We are looking forward to advancing DNL593 independently," CEO Ryan Watts said in a press statement that day, adding that the company "remain[s] confident" in the scientific rationale behind DNL593. DNL593 works by replacing the progranulin protein, which in frontotemporal dementia is deficient, leading to lysosomal defects that, in turn, result in the accumulation of toxins across different tissues. The asset is currently in a Phase 1/2 study, enrollment for which has completed with 40 recruited participants, according to Denali's April 3 release. There have been no reported safety signals to date, the biotech noted. Phase 1/2 data for DNL593 are expected before the end of this year, Watts said. Takeda's pullback comes just days after Denali delivered a much-needed win for the rare disease space with the FDA approval of its Hunter syndrome therapy Avlayah. Like DNL593, Avlayah works by replacing a deficient player, this time targeting the IDS enzyme, which under healthy conditions clears toxic byproducts from several organs, including the brain. Avlayah is the first Hunter syndrome therapy in nearly 20 years and is the first FDA-approved treatment to exploit the transferrin pathway to cross the blood-brain barrier. Avlayah is the first Hunter syndrome therapy approved to address the condition's neurologic complications, according to Tracy Beth Høeg, acting director of the Center for Drug Evaluation and Research. March 26, 2026

The Boston Globe
Mar 31st, 2026
Pharma giant Takeda to lay off nearly 250 local workers in latest job cutting.

Pharma giant Takeda to lay off nearly 250 local workers in latest job cutting. By Marin Wolf Globe Staff, Updated March 30, 2026, 10:00 a.m. Takeda Pharmaceuticals will lay off nearly 250 workers in Cambridge, the state's largest biopharma employer announced through a state filing. The layoffs will begin in July, although some will take place later in the year or in 2027. All affected Massachusetts employees work at the company's 500 Kendall St. location, according to the filing posted Friday. The workforce reduction is part of a cost-saving plan approved by Takeda's board of directors on March 25 that is expected to result in annual savings of about $1.25 billion by 2028, according to a company statement. Another 387 workers in other states may also be laid off as part of the plan.

Yahoo Finance
Mar 30th, 2026
Takeda Pharmaceuticals to cut 247 jobs in Cambridge as part of $1.2B cost-cutting plan

Takeda Pharmaceuticals, Massachusetts' largest biopharmaceutical employer, will lay off 247 employees at its Cambridge headquarters as part of a broader corporate restructuring. The redundancies begin on 1 July and could extend into 2027. The Japanese company announced cost-cutting measures expected to save approximately $1.2 billion by 2028. An additional 387 employees will be laid off in other US states. Affected workers are receiving transition assistance, including help identifying internal opportunities. Takeda currently has around 700 open positions, including 300 in Massachusetts, with internal candidates given priority. The company employs more than 5,700 people in Massachusetts and occupies approximately 2.8 million square feet of real estate. This follows 137 layoffs announced in October and over 800 Massachusetts redundancies in 2024.

BioSpace
Mar 30th, 2026
Takeda restructuring could push more than 600 US staffers out of jobs.

Takeda restructuring could push more than 600 US staffers out of jobs. March 30, 2026 | Takeda's layoffs include cutting 247 people in Massachusetts. The workforce reduction is meant to help offset investments in areas including a product launch for oral drug candidate zasocitinib, for which the pharma today announced positive Phase 3 data. The workforce impact of Takeda's recently announced reorganization has become clearer. The Japan-based pharma estimates the restructuring will affect around 634 U.S. employees, according to a Worker Adjustment and Retraining Notification (WARN) Act notice. Takeda began notifying employees on March 25, the same day it announced a business transformation, which includes streamlining corporate functions. However, the company noted in the WARN notice that the total number affected could change as staff pursue and accept redeployment opportunities across its global network. Takeda's cuts include 247 employees in Cambridge, Massachusetts, effective July 1, 2026, through Dec. 31, 2027. To understand where other layoffs will take place, BioSpace has requested a copy of a document mentioned in the WARN notice that lists the number of individuals affected by state. In last week's announcement, Takeda noted that the restructuring, which includes "strategically prioritizing resources," is expected to save more than 200 billion yen - about $1.25 billion - by fiscal year 2028. The company explained that the savings will offset investments needed to prepare for multiple launches, including oveporexton, usfertide and zasocitinib; progress the late-stage pipeline; and support strategic technology investments. Takeda announced today promising data for zasocitinib, an oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate to severe plaque psoriasis. In the Phase 3 Latitude PsO 3001 and 3002 studies, more than half of patients treated with the drug candidate achieved clear or almost clear skin at week 16, a key measure of treatment success, according to the pharma. Zasocitinib also demonstrated statistically significant improvements in complete skin clearance. Takeda expects to submit a new drug application for zasocitinib in fiscal year 2026. The pharma acquired zasocitinib from Nimbus Therapeutics for $4 billion at the end of 2022 to challenge Bristol Myers Squibb's kinase inhibitor Sotyktu. Takeda in December 2025 reported positive results from the Phase 3 LATITUDE studies, noting that when compared with placebo and Amgen's Otezla, about 30% of treated patients achieved completely clear skin, or a score of 100 on the Psoriasis Area and Severity Index (PASI). The company's latest layoffs join a series of cuts from the past two years. Takeda let go of nearly 1,500 employees in the U.S. and Austria in 2024 and early 2025 and 137 in October 2025. In January, news broke that 243 people would be laid off across its U.S. operations.

Healthcare Asia Magazine
Mar 30th, 2026
Takeda Healthcare Philippines, Inc. wins at Healthcare Asia Pharma Awards 2026.

Takeda Healthcare Philippines, Inc. wins at Healthcare Asia Pharma Awards 2026. The access programme and advocacy initiative closed affordability gaps for Filipino patients. Takeda Healthcare Philippines, Inc. won Most Differentiated Service of the Year - Philippines and Patient Advocacy Program of the Year - Philippines in the Healthcare Asia Pharma Awards 2026 for its access model that supports patients from disease awareness to therapy completion. In a healthcare system where many patients face delayed diagnosis, long referral pathways, and high out-of-pocket costs, the company built a differentiated and sustainable service anchored on its Patient Assistance Program (PAP). The programme follows a clear principle: therapy completion should not depend on a patient's ability to pay. PAP uses an affordability-based assessment to evaluate each eligible patient's circumstances and set a contribution aligned to what the patient can reasonably afford for the full course of treatment. This structured, patient-level approach supports equity whilst maintaining business viability. It is not a standard discount model but a tailored access scheme designed for Filipino patients and adaptable to changing circumstances. The operating model involves independent third parties assessing financial support needs and informing programme design. Patients share in the cost of treatment, whilst Takeda Healthcare Philippines, Inc. collaborates with local authorities and partners to help cover the remaining cost. The company embeds access within hospital pathways through collaborations with organisations such as the Tzu Chi Foundation, private institutions, and major hospitals, helping reduce out-of-pocket expenses and improve coordination across the patient journey. Join Healthcare Asia Magazine community To date, more than 1,300 Filipino patients have received support through Takeda's access programme, including patients living with Hodgkin lymphoma, inflammatory bowel disease, and other rare conditions. By enabling therapy completion, the programme helps patients return to work or school and resume caregiving roles, reducing the broader social and economic burden of untreated disease. Beyond affordability, the company addresses inequity in geographically isolated and disadvantaged areas by working with partners to strengthen patient navigation and connections to appropriate providers and specialists. Through Access to Medicines Summits and partnership frameworks, it also supports patients in accessing available private and government funding. A key milestone in its advocacy efforts is the inclusion of life-saving treatment for rare diseases such as haemophilia in the Philippine National Formulary, enabling free access to essential medicines in government hospitals following partnerships and a positive health technology assessment. The Healthcare Asia Pharma Awards shines a spotlight on the outstanding companies redefining pharmaceutical excellence in Asia. It lauds those who redefine the pharmaceutical landscape through innovative, unique initiatives that have significantly enhanced their businesses. The Healthcare Asia Pharma Awards is presented by Healthcare Asia Magazine. To view the full list of winners, click here. If you want to join the 2027 awards programme and be recognised for your organisation's innovative and unique initiatives that enhanced your business and remarkable contributions to the pharmaceutical industry, please contact Julie Anne Nuñez-Difuntorum at [email protected].

INACTIVE